CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider

uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to

tisagenlecleucel. However, several questions remain unresolved. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS

OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn

FAQs * Contact customer support REFERENCES * Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. _Bone Marrow

Transplant._ 55, 538–543 (2020). Article  Google Scholar  * Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow

transplant clinical trials network 0201 trial. _Biol. Blood Marrow Transplant._ 21, 1815–1822 (2015). Article  Google Scholar  * Bachy, E. et al. A real-world comparison of tisagenlecleucel

and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. _Nat. Med._ 28, 2145–2154 (2022). Article  CAS  Google Scholar  * Brookhart, M. A. et al.

Variable selection for propensity score models. _Am. J. Epidemiol._ 163, 1149–1156 (2006). Article  Google Scholar  * Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell

therapies for large B-cell lymphoma in Germany. _Blood_ 140, 349–358 (2022). CAS  Google Scholar  * Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or

refractory aggressive B-NHL. _Blood_ 139, 3722–3731 (2022). Article  CAS  Google Scholar  * Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of

commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. _Transplant Cell Ther._ 28, 669–676 (2022). Article  Google Scholar  * Oluwole,

O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. _Br. J. Haematol._ 194, 690–700 (2021). Article  CAS  Google Scholar  *

NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. _nice.org.uk_, https://www.nice.org.uk/guidance/ta554 (21

December 2022). * ICER. Leukemia and Lymphoma. _icer.org_ https://icer.org/assessment/leukemia-and-lymphoma-2018 (March 2018). Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS

* Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA Richard T. Maziarz * Clinical Research Division, Fred Hutchinson

Cancer Center, Seattle, WA, USA Jordan Gauthier * Department of Medicine, University of Washington, Seattle, WA, USA Jordan Gauthier Authors * Richard T. Maziarz View author publications You

can also search for this author inPubMed Google Scholar * Jordan Gauthier View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR

Correspondence to Richard T. Maziarz. ETHICS DECLARATIONS COMPETING INTERESTS R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR

Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and

MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi. RIGHTS AND PERMISSIONS Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Maziarz, R.T., Gauthier, J. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. _Nat Rev Clin Oncol_ 20, 5–6 (2023).

https://doi.org/10.1038/s41571-022-00711-4 Download citation * Published: 15 November 2022 * Issue Date: January 2023 * DOI: https://doi.org/10.1038/s41571-022-00711-4 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative